NASDAQ:ABUS Arbutus Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.71 +0.01 (+0.37%) (As of 06/30/2022 05:48 PM ET) Add Compare Share Today's Range$2.62▼$2.7650-Day Range$1.98▼$2.9252-Week Range$1.93▼$6.50Volume585,847 shsAverage Volume1.90 million shsMarket Capitalization$403.05 millionP/E RatioN/ADividend YieldN/APrice Target$7.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock Forecast (MarketRank)Overall MarketRank™1.66 out of 5 starsMedical Sector950th out of 1,433 stocksPharmaceutical Preparations Industry474th out of 684 stocksAnalyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.13, Arbutus Biopharma has a forecasted upside of 164.9% from its current price of $2.69.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 4.8 Community Rank Outperform VotesArbutus Biopharma has received 412 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArbutus Biopharma has received 168 “underperform” votes. (Add your “underperform” vote.)Community SentimentArbutus Biopharma has received 71.03% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote “Outperform” if you believe ABUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by InstitutionsOnly 26.66% of the stock of Arbutus Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.51) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arbutus Biopharma (NASDAQ:ABUS)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Stock News HeadlinesJune 28, 2022 | finance.yahoo.comThis Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis BJune 25, 2022 | finance.yahoo.comArbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical UpdateJune 25, 2022 | finance.yahoo.comArbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical UpdateJune 8, 2022 | finance.yahoo.comArbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022June 6, 2022 | finance.yahoo.comWe Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business GrowthJune 6, 2022 | seekingalpha.comArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentJune 2, 2022 | finance.yahoo.comArbutus to Participate in June Investor ConferencesMay 26, 2022 | finance.yahoo.comArbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 17, 2022 | finance.yahoo.comArbutus to Present at H.C. Wainwright Global Investment ConferenceMay 7, 2022 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Earnings ForecastsMay 5, 2022 | nasdaq.comArbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2022 | finance.yahoo.comArbutus Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 4, 2022 | finance.yahoo.comAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue EstimatesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees85Year Founded1992Company Calendar Last Earnings5/05/2022Today6/30/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.13 High Stock Price Forecast$9.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+162.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.730010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76.25 million Net Margins-352.49% Pretax Margin-331.78% Return on Equity-121.30% Return on Assets-40.75% Debt Debt-to-Equity RatioN/A Current Ratio5.33 Quick Ratio5.33 Sales & Book Value Annual Sales$10.99 million Price / Sales36.67 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book2.32Miscellaneous Outstanding Shares148,728,000Free Float140,994,000Market Cap$403.05 million OptionableOptionable Beta2.66 Social Links Arbutus Biopharma Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock. View analyst ratings for Arbutus Biopharma or view top-rated stocks. What is Arbutus Biopharma's stock price forecast for 2022? 4 analysts have issued 12-month price targets for Arbutus Biopharma's shares. Their ABUS stock forecasts range from $5.00 to $9.00. On average, they expect Arbutus Biopharma's share price to reach $7.13 in the next year. This suggests a possible upside of 162.9% from the stock's current price. View analysts' price targets for Arbutus Biopharma or view top-rated stocks among Wall Street analysts. How has Arbutus Biopharma's stock performed in 2022? Arbutus Biopharma's stock was trading at $3.89 at the start of the year. Since then, ABUS shares have decreased by 30.3% and is now trading at $2.71. View the best growth stocks for 2022 here. When is Arbutus Biopharma's next earnings date? Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Arbutus Biopharma. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company earned $12.58 million during the quarter, compared to analyst estimates of $5.77 million. Arbutus Biopharma had a negative net margin of 352.49% and a negative trailing twelve-month return on equity of 121.30%. During the same quarter in the previous year, the firm posted ($0.21) EPS. View Arbutus Biopharma's earnings history. Who are Arbutus Biopharma's key executives? Arbutus Biopharma's management team includes the following people: Mr. William H. Collier, Pres, CEO & Director (Age 62, Pay $1.03M)Mr. David C. Hastings CPA, CFO & Chief Accounting Officer (Age 61, Pay $647.1k)Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 64, Pay $670.22k)Ms. Lisa M. Caperelli, VP of Investor RelationsDr. Elizabeth Howard, Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 68)Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 58)Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 47)Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., Sec. (Age 71) What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Arbutus Biopharma's key competitors? Some companies that are related to Arbutus Biopharma include Lyell Immunopharma (LYEL), BELLUS Health (BLUSF), Dynavax Technologies (DVAX), Emergent BioSolutions (EBS), Supernus Pharmaceuticals (SUPN), Travere Therapeutics (TVTX), Cryoport (CYRX), Ligand Pharmaceuticals (LGND), Axsome Therapeutics (AXSM), Aurinia Pharmaceuticals (AUPH), Taro Pharmaceutical Industries (TARO), Sierra Oncology (SRRA), BridgeBio Pharma (BBIO), Day One Biopharmaceuticals (DAWN) and Zentalis Pharmaceuticals (ZNTL). View all of ABUS's competitors. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." How do I buy shares of Arbutus Biopharma? Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $2.71. How much money does Arbutus Biopharma make? Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $403.05 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76.25 million in net income (profit) each year or ($0.730010) on an earnings per share basis. How many employees does Arbutus Biopharma have? Arbutus Biopharma employs 85 workers across the globe. When was Arbutus Biopharma founded? Arbutus Biopharma was founded in 1992. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for Arbutus Biopharma is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201. This page (NASDAQ:ABUS) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
